GlassScriptPhysician profile
Bailey Shunyakov
NPI 1912560038
$26,775.45
in general payments reported to CMS, 2019-2025
73 companies · $7,713 in 2025
The $7,713 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,078 · 2022: $6,005 · 2023: $4,222 · 2024: $6,758 · 2025: $7,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $6,962 · Education: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,319.47 |
| Consulting Fee | $6,961.50 |
| Education | $411.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $4,322.15 | 2021-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $2,675.07 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $2,309.84 | 2021-2025 | Talvey, Erleada, Darzalex |
| Genentech USA, INC. | $1,966.05 | 2021-2025 | Venclexta, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $1,329.32 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Celgene Corporation | $1,196.32 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,091.87 | 2021-2025 | |
| Abbvie INC. | $925.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $774.41 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $739.76 | 2021-2025 | Retevmo, Jaypirca, Verzenio |
| Seagen INC. | $721.74 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Gilead Sciences, INC. | $600.08 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $541.40 | 2021-2025 | |
| Eisai INC. | $490.08 | 2021-2025 | |
| Amgen INC. | $464.96 | 2021-2025 | Imdelltra (Amg757), Kyprolis, Lumakras |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $406.90 | 2021-2025 | Xpovio |
| Novocure INC. | $388.69 | 2023-2024 | Optune, Optune Lua (Novottf-200t) |
| Pfizer INC. | $384.37 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $372.61 | 2021-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $365.28 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $303.04 | 2021-2024 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $226.95 | 2021-2025 | |
| Exelixis INC. | $224.61 | 2022-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $222.66 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.75 | 2021-2025 | Gilotrif |
| Incyte Corporation | $175.05 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $172.89 | 2022-2025 | Iclusig, Alunbrig, Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $164.04 | 2022-2025 | Tazverik |
| Kite Pharma, INC. | $159.52 | 2021-2025 | Yescarta |
| Stemline Therapeutics INC. | $151.87 | 2023-2025 | Orserdu |
| Recordati_rare_diseases_inc. | $143.97 | 2023-2025 | Enjaymo, Panhematin |
| Pharmacyclics LLC, An Abbvie Company | $133.65 | 2022-2023 | Imbruvica |
| Kyowa Kirin, INC. | $128.75 | 2021-2024 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $126.04 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $123.07 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $120.25 | 2022 | |
| Array Biopharma INC | $110.45 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Sobi, INC | $110.27 | 2022-2025 | |
| Caris Mpi, INC. | $109.43 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $109.25 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| G1 Therapeutics, INC. | $86.54 | 2022-2023 | Cosela |
| Epizyme, INC. | $86.48 | 2021-2022 | |
| Genentech, INC. | $85.17 | 2024 | Tecentriq |
| Genmab U.S., INC. | $79.90 | 2023-2025 | Tivdak, Epkinly |
| Organon LLC | $74.08 | 2022-2023 | Ontruzant |
| Tersera Therapeutics LLC | $72.46 | 2021-2022 | |
| Puma Biotechnology, INC. | $72.15 | 2022-2024 | Nerlynx |
| Mirati Therapeutics, INC. | $68.15 | 2023-2024 | Krazati |
| Beigene USA, INC. | $63.32 | 2021-2022 | |
| Beone Medicines USA, INC. | $62.08 | 2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $59.81 | 2022 | |
| Mylan Institutional INC. | $58.14 | 2022-2023 | Fulphila, Ogivri |
| Springworks Therapeutics, INC. | $54.03 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $45.38 | 2023-2024 | Empaveli |
| Pharmacosmos Therapeutics INC. | $44.10 | 2022-2024 | Cosela |
| Syndax Pharmaceuticals, INC. | $42.81 | 2025 | |
| Astellas Pharma US INC | $39.42 | 2023 | Cresemba |
| Sun Pharmaceutical Industries INC. | $39.18 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $38.62 | 2023-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $38.04 | 2022 | |
| Pharmaand Gmbh | $24.42 | 2024 | Rubraca |
| Amneal Pharmaceuticals LLC | $21.59 | 2023 | Neulasta, Avastin, Neupogen |
| Alexion Pharmaceuticals, INC. | $20.84 | 2024 | Ultomiris |
| Corcept Therapeutics | $19.61 | 2025 | Korlym |
| Menarini Silicon Biosystems, INC. | $18.54 | 2023 | Cellsearch |
| Amag Pharmaceuticals, INC. | $15.90 | 2021 | |
| Spectrum Pharmaceuticals INC. | $15.77 | 2025 | Rolvedon |
| Eusa Pharma (US) LLC | $15.31 | 2022 | |
| Accord Healthcare, INC. | $14.70 | 2023 | |
| Pharmaessentia USA Corporation | $14.29 | 2024 | Besremi |
| Alnylam Pharmaceuticals INC. | $13.51 | 2023 | Givlaari |
| Grifols USA, LLC | $13.10 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
Enhertu $3,855Venclexta $1,735Reblozyl $649Datroway $506Keytruda $494Epkinly $323Opdivo $318Lenvima $317Scemblix $312Imbruvica $309Optune $295Libtayo $277Kisqali $219Zepzelca $215Lynparza $213Tavalisse $201Rezlidhia $201Imfinzi $199Retevmo $190Sarclisa $186Talvey $186Erleada $178Cabometyx $173Jaypirca $171Pomalyst $170Darzalex $169Xpovio $155Orserdu $152Verzenio $150Tecentriq $149Opdualag $149Enjaymo $145Polivy $130Lunsumio $127Trodelvy $123Imdelltra (Amg757) $122Tazverik $118Tasigna $115Fotivda $113Mi Cancer Seek $109Tukysa $107Columvi $101Orgovyx $96.06Carvykti $94.13Optune Lua (Novottf-200t) $93.40Tecvayli $90.93Krazati $89.70Yescarta $88.64Padcev $75.01Stivarga $74.76Xtandi $71.28Rybrevant $71.16Welireg $68.95Phesgo $66.64Fabhalta $64.44Ojjaara $63.99Cosela $60.55Talzenna $57.44Perjeta $56.81Ibrance $54.45Ogsiveo $54.03Iclusig $53.97Balversa $53.13Jakafi $51.03Kyprolis $49.94Gilotrif $48.39Alunbrig $48.16Piqray $48.12Poteligeo $48.08Braftovi $47.65Xalkori $47.65Mektovi $47.65Lorbrena $47.65Empaveli $45.38Adcetris $45.18Emrelis $44.28Herceptin $44.05Kadcyla $44.05Vitrakvi $42.45Tivdak $41.90Cresemba $39.42Promacta $39.09Monjuvi $38.70Nubeqa $37.85Cablivi $37.70Panhematin $36.54Jemperli $34.07Zejula $34.07Inqovi $33.98Lonsurf $33.98Ontruzant $32.75Brukinsa $32.74Jevtana $31.50Tevimbra $29.34Itovebi $26.63Yonsa $26.40Odomzo $26.40Lumakras $25.52Rubraca $24.42Fruzaqla $21.85
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Shunyakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.